This index provides comprehensive coverage of investment landscape, funding strategies, and therapeutic development in the neurodegenerative disease field. It tracks pharmaceutical company pipelines, clinical trial investments, venture funding, and partnership activities across Alzheimer's disease, Parkinson's disease, ALS, and related disorders.
The neurodegenerative disease investment landscape has evolved significantly over the past decade, with increased focus on disease-modifying therapies, precision medicine approaches, and biomarker-driven clinical trials.
Major pharmaceutical companies maintain active pipelines for neurodegenerative diseases:
Total: 97 investment pages